Researchers from the Massachusetts Institute of Technology (MIT) and Scripps Research have discovered an innovative way to enhance the immune response against the HIV virus with just a single vaccine dose by combining two powerful immune boosters.
In an experiment conducted on mice, the results showed that the combination of the traditional alum and a new stimulant known as SMNP led to a greater quantity and diversity of antibodies compared to using the vaccine alone or with only one stimulant.
This advancement is promising not only for combating HIV but also for developing vaccines for other infectious diseases like COVID-19 and influenza, through the design of effective one-time vaccines.
The researchers used a modified protein from the HIV virus called MD39 as an antigen, which was attached to alum particles along with SMNP. After vaccination, they observed that this mixture stabilized in the lymph nodes for up to a month, allowing more time to build a robust and targeted immune response.
Professor J. Christopher Lave, one of the senior study authors, explained: "This approach closely resembles what happens during a natural infection, where the antigen remains in the body for an extended period, giving immune cells the chance to enhance their defenses."
By analyzing the B cells in the vaccinated mice, the researchers found that the enhanced vaccine produced a larger and more diverse array of antibodies, increasing the chances of generating broadly neutralizing antibodies capable of recognizing multiple strains of HIV.
Lave added, "The more opportunities we give the immune system to explore solutions, the greater our ability to produce effective antibodies against a broader spectrum of viruses."
The study, published in the journal Science Translational Medicine, indicates that this technique can be applied to protein-based vaccines against various diseases, and the materials used are already recognized by health authorities, facilitating quicker adoption in the future.
Lave concluded, "What truly makes this approach promising is its simplicity and effectiveness; we don’t need new technologies, but rather to use what we have more intelligently to develop stronger and faster-acting vaccines."
This research was funded by the National Institutes of Health, the Koch Institute, the Rajon Institute, and the Howard Hughes Medical Institute.
